AstraZeneca's newly acquired Soliris is overpriced in myasthenia gravis, cost watchdog says
23rd July 2021 Uncategorised 0 AstraZeneca’s newly acquired Soliris is overpriced in myasthenia gravis, cost watchdog says
nhigginsdunn
Fri, 07/23/2021 – 14:46
More: AstraZeneca's newly acquired Soliris is overpriced in myasthenia gravis, cost watchdog says
Source: fierce